CHICAGO – Nucleai, a developer of a bioinformatics platform for precision oncology research and clinical decision support, may be a startup, but its technology has been proven over more than two decades.
CEO Avi Veidman and several colleagues started the company in 2017. He previously spent nearly 20 years in Israeli military intelligence, where he led a department that applied artificial intelligence and machine learning to the analysis of satellite and aerial images. Eventually, he decided that he wanted to establish a company at the nexus of big data and biology.